SCHEMBL5021990

SCHEMBL5021990

COc1cccc([C@H]2OC(=O)N[C@@H]2c2cccc(-c3cnc4ccccc4c3)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.57
PDGFRB P09619 2/20 0.44
PDGFRA P16234 1/20 0.44
MAP4K4 O95819 1/20 0.44
CSNK1G2 P78368 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
MAP4K5 Q9Y4K4 1/20 0.44
BIRC5 O15392 1/20 0.40
ALDH1A1 P00352 1/20 0.40
F2 P00734 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
ALPL P05186 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363924 0.85 GRM5 (0.52) GRM5PDGFRBPDGFRABRD4CA12
SCHEMBL5021381 0.84 GRM5 (0.73) GRM5ALDH1A1KMT2A
SCHEMBL5021912 0.84 GRM5 (0.73) GRM5ALDH1A1KMT2A
SCHEMBL5027157 0.84 GRM5 (0.73) GRM5ALDH1A1KMT2A
SCHEMBL5021180 0.84 GRM5 (0.73) GRM5ALDH1A1KMT2A
SCHEMBL5021739 0.84 GRM5 (0.69) GRM5ALDH1A1KMT2AGAA
SCHEMBL5021776 0.84 GRM5 (0.59) GRM5PDGFRBKMT2AGAA
SCHEMBL13585009 0.84 GRM5 (0.73) GRM5
SCHEMBL5021795 0.83 GRM5 (0.58) GRM5PDGFRBALDH1A1F2HPGD
SCHEMBL5021840 0.83 GRM5 (0.57) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY 2012-11-08 US disclosed
WO-2012064603-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 GRM5, GRIK5, GRM1 GRM5 1/4885PDGFRB 2526/4885PDGFRA 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.